2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Pediatric, Young Adult
PAPER

4881 Acute degradation of GATA2 in myeloid progenitor cells reveals a core repressive maintenance function

Apoorva Patil, MS, Trey Gilpin, PhD2, Peng Liu, PhD3, Daniel Rusch Matson, MD, PhD4
1 University of Wisconsin - Madison, Madison, Wisconsin, United States
2 University of Wisconsin - Madison, Madison, Wisconsin, United States
3 University of Wisconsin - Madison, Madison, Wisconsin, United States
4 University of Wisconsin - Madison, Madison, Wisconsin, United States
Background: GATA Binding Protein 2 (GATA2) is a zinc finger transcription factor that is essential for the production and maintenance of hematopoietic stem and progenitor cells (HSPCs). Persons born with germline GATA2 haploinsufficiency are initially healthy but go on to develop immunodeficiency, bone marrow failure, and progression to myelodysplastic syndrome and acute myeloid leukemia. Nearly all models of GATA2 function are derived from germline or conditional knockout or mutation of GATA2 or enhancers that regulate its expression. Such approaches have defined the foundational transcriptional and regulatory programs that GATA2 is required to establish. However, they cannot resolve whether and how these programs are maintained by GATA2 after they are established. We reasoned that acute degradation of GATA2 protein from an established progenitor would enable separation of these two functions and allow us to elucidate transcriptional networks that are actively maintained by GATA2 in the steady state.

Methods: We generated a mouse model in which endogenous Gata2 is fused in-frame to a drug-inducible degron (SMASh). This permitted rapid, tunable, and reversible depletion of all GATA2 protein upon treatment with FDA-approved drugs. In the absence of drug (steady state) homozygous knock-in mice were born at normal Mendelian ratios, had normal bone marrow cellularity, maintained peripheral blood counts indistinguishable from wildtype controls, and remained healthy beyond 1 year of age. From these animals we derived HoxB8-immortalized myeloid progenitor cells which supported well-controlled time courses at scale. To read out direct transcriptional consequences rather than steady-state mRNA, we activated GATA2 degradation and performed SLAMseq (thiol-linked alkylation of 4-thiouridine-labeled RNA), quantifying nascent transcription at 3, 6, and 10 hours after degron activation (2 replicates per timepoint; SLAMdunk, FDR<0.05). Existing GATA2 Cut&Tag dataset from lineage-matched HoxB8-immortalized cells was performed as described (Tran et al., 2025).

Results: GATA2 protein fell to 85%, 44%, and 5% of baseline at 3, 6, and 10 hours, respectively. At 3 hours, nascent transcription was stable and no differentially transcribed genes (DTGs) were identified. At 6 hours, nascent transcription remained strikingly stable and only 3 DTGs were identified, all decreased vs control (Tceanc, Tmem237, Dctn4; log2fold change -1.9 to -4.6). At 10 hours, 193 DTGs were detected, and unexpectedly 184 of 193 (95%) were increased vs control. The de-repressed genes were markedly enriched for transcriptional and chromatin regulators, including Runx1, Cebpb, Mef2c, Klf3, Hlx, Zbtb7a, Cbfa2t3, Pou2f1, Pou2f2, Arid5b, Irf2bp2, Nfic, Tgif2, Hic1, Rest, Mecp2, Kmt2a, Kdm6b, Setd2, Chd1, and Chd2. Only 12 DTGs (5%) were decreased vs control, but these were enriched for the most abundantly transcribed genes in the dataset and were weighted toward core translational and biosynthetic machinery (Eef1a1, Ran, Rpl10a, Rps13, Atp5g3, Ints8). Regions flanking the transcription start site of DTGs were greatly enriched for GATA2 occupancy by GATA2 Cut&Tag.  Among DTGs with increased log2fold change, the magnitude of the GATA2 occupancy signal showed a significant negative correlation with log2fold change in DTG nascent transcription (r=-0.22, p<0.0001), indicating that greater GATA2 occupancy correlated with greater DTG repression.

Conclusions: Our findings support a model in which a principal function of GATA2 in myeloid progenitor cells is to actively restrain a broad network of transcriptional and chromatin regulators. The strong negative correlation between the magnitude of GATA2 occupancy at DTG loci and the magnitude of DTG repression suggests that GATA2 may directly repress DTG targets or that GATA2 may actively modulate the localization or activity of other direct-acting factors. The kinetics of nascent transcription during GATA2 degradation indicate that even after 50% loss of GATA2 protein, GATA2 transcriptional regulation at GATA2 target genes remains largely intact. However, further loss of GATA2 protein triggers rapid de-repression of transcriptional and chromatin regulators, and prominent repression of a smaller number of core translational and biosynthetic factors. Future studies will washout degron-activating drug following GATA2 depletion and kinetically map restoration of nascent DTG transcription as GATA2 protein returns to wildtype levels.
Daniel Rusch Matson, MD, PhD: No relevant conflicts of interest to declare.